⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LPCN News
Lipocine Inc.
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025
prnewswire.com
LPCN
Form 8-K
sec.gov
LPCN
Form 8-K
sec.gov
LPCN
New to The Street and Wall Street New York Magazine Launch Weekly Executive Publication with Integrated NewsOut Video Press Distribution
accessnewswire.com
VRTX
NRXP
ONCO
LPCN
RDZN
BIVI
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
prnewswire.com
LPCN
2026 Asset Growth: Why Federal Compliance Is the New Metric
globenewswire.com
CGC
DFTX
LPCN
KDP
Buprenorphine Patches Market Forecast Intelligence Report 2026-2032: Global, Regional and Country-Level Coverage
globenewswire.com
AMRX
VRTS
TEVA
LPCN
SUN
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
prnewswire.com
LPCN
ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
businesswire.com
ABT
AL
GEHC
MED
LH
PHG
LPCN
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
prnewswire.com
LPCN